| PUBLICATIONS (Ranked by impact factor of the journal) | LABORATORY RESEARCH Recreating the Tumor Microenvironment in a Bilayer, Hyaluronic Acid Hydrogel Construct for the Growth of Prostate Cancer Spheroids Researchers developed and characterized a hyaluronic acid-based bilayer hydrogel system that not only supports the tumoroid formation from LNCaP prostate cancer cells, but also simulates their reciprocal interactions with the tumor-associated stroma. [Biomaterials] Abstract Phosphorylation of the Androgen Receptor by PIM1 in Hormone Refractory Prostate Cancer Bioinformatic analysis revealed androgen receptor (AR) serine 213 (S213) as a putative substrate for PIM1, a kinase overexpressed in prostate cancer. Therefore, phosphorylation of AR s213 by PIM1 was examined using a phosphorylation site-specific antibody. [Oncogene] Abstract Targeting the Unique Methylation Pattern of AR Promoter in Prostate Stem/Progenitor Cells with 5-AZA Leads to Suppressed Prostate Tumorigenesis Researchers found normal prostate/prostate cancer (PCa) stem/progenitor cells expressed little androgen receptor (AR) with high methylation in the AR promoter. The low expression of AR in normal prostate/PCa stem/progenitor cells was reversed after adding 5-Aza-2-deoxycytidine (5-AZA) which lead to decreased stemness and drive cells into a more differentiated status. [J Biol Chem] Abstract | Full Article Increased Expression of Activated Endothelial Nitric Oxide Synthase Contributes to Antiandrogen Resistance in Prostate Cancer Cells by Suppressing Androgen Receptor Transactivation Investigators demonstrated that endothelial nitric oxide synthase exhibited an overexpression pattern in hormone-refractory prostate cancer and several models of advanced hormone-resistant prostate cancer. [Cancer Lett] Abstract Myeloid Cell Leukemia-1 Is a Key Molecular Target for Mithramycin A-Induced Apoptosis in Androgen-Independent Prostate Cancer Cells and a Tumor Xenograft Animal Model The authors examined the critical role of mithramycin A (Mith) in apoptosis and its molecular mechanism in DU145 and PC3 prostate cancer cells and tumor xenografts. It was found that Mith inhibits cell growth and induces apoptosis by suppressing myeloid cell leukemia-1 in both prostate cancer cells and xenograft tumors. [Cancer Lett] Abstract Functional p53 Determines Docetaxel Sensitivity in Prostate Cancer Cells The potential role of p53 in docetaxel sensitivity in prostate cancer cells was tested by either p53 silencing using shRNA or p53 overexpression by introducing wild-type p53. Scientists found that DU145 and PC3 cells were less sensitive than LNCaP and C4-2 cells expressing functional p53 in response to docetaxel. [Prostate] Abstract The Combination of Plumbagin with Androgen Withdrawal Causes Profound Regression of Prostate Tumors In Vivo This study assessed the efficacy of a new therapeutic strategy that combines plumbagin, a naturally occurring naphthoquinone, with androgen ablation. The mechanism of action of plumbagin was explored using human and mouse prostate cancer cells. [Prostate] Abstract The Expression of URGCP Gene in Prostate Cancer Cell Lines: Correlation with Rapamycin Rapamycin (RPM) is an antifungal macrolide antibiotic isolated from Streptomyces hygroscopicus which can inhibit the G1 to S transition. Upregulator of cell proliferation (URGCP) is a novel gene located on chromosome 7p13; the authors investigated the role of URGCP gene expression changes in PC3, DU145, and LNCAP cell lines with and without RPM. [Mol Biol Rep] Abstract Dual Roles of PARP-1 Promote Cancer Growth and Progression Data demonstrated that poly(ADP-ribose) polymerase-1 (PARP-1) elicits pro-tumorigenic effects in androgen receptor-positive prostate cancer cells, both in the presence and absence of genotoxic insult. [Cancer Discovery] Abstract CLINICAL RESEARCH Contrast Enhanced Transrectal Ultrasound for the Detection of Prostate Cancer: A Randomized, Double-Blind Trial of Dutasteride Pretreatment Researchers quantified prostate cancer detection with contrast enhanced ultrasound with or without short-term pretreatment with dutasteride. [J Urology] Abstract | Press Release |
|
|
|